Acoramidis didn't just cut deaths in heart amyloidosis — patients felt the difference

Acoramidis, a pill that stabilises the transport protein whose misfolding scars the heart in transthyretin amyloid cardiomyopathy, does more than lower deaths and hospital admissions — it measurably slowed the decline in how patients rated their own health, according to a prespecified analysis of the phase 3 ATTRibute-CM trial [s1]. Over 30 months the drug held back the loss of heart-failure–related quality of life by nearly 10 points on a standard questionnaire, and at the end of the trial one extra patient was kept "alive and not worse" for every six treated [s1].

Transthyretin amyloid cardiomyopathy, or ATTR-CM, is caused by the protein transthyretin (TTR) breaking apart, misfolding and depositing as amyloid fibrils in heart muscle, which stiffens the walls and drives progressive heart failure. It was long considered rare and untreatable; better imaging has shown it to be underdiagnosed, and a small class of drugs now targets it. Acoramidis works by binding TTR and holding its four-part structure together. The trial paper reports more than 90% stabilisation across the dosing interval when measured in the lab [s2]; that laboratory figure is a mechanistic marker, and the outcome data below are what the randomised trial and its peer-reviewed analysis actually showed in patients.

What the trial measured

ATTRibute-CM was a phase 3, double-blind trial that randomly assigned 632 patients with ATTR-CM in a 2:1 ratio to acoramidis hydrochloride 800 mg twice daily or placebo for 30 months [s2]. Its primary result, reported in 2024, used a hierarchical analysis combining death from any cause, cardiovascular hospitalisation, and changes in a heart-failure blood marker and walking distance; it favoured acoramidis with a win ratio of 1.8 (95% confidence interval 1.4 to 2.2), meaning that when patients were compared in pairs, 63.7% of comparisons favoured the drug and 35.9% favoured placebo [s2].

Those are clinician-measured endpoints. The newer analysis asked a different and arguably more human question: did patients feel better? It used the Kansas City Cardiomyopathy Questionnaire Overall Summary score (KCCQ-OS), a validated 0-to-100 scale of heart-failure symptoms and daily function on which higher is better [s1]. This is exactly the kind of patient-reported measure that a disease-slowing drug can improve on paper without patients noticing — or can move in a way they feel.

What it found

Among 611 patients in the analysis, the average age was 77.2 years and only 9.2% were women — the skew typical of this disease [s1]. Baseline KCCQ-OS scores were similar, at 71.7 in the acoramidis group (409 patients) and 70.5 in the placebo group (202 patients) [s1]. By month 30 the drug had preserved health status: a least-squares mean difference of 9.9 points in its favour (95% confidence interval 6.0 to 13.9), a gap generally regarded as clinically meaningful, not just statistically detectable [s1].

The analysis then sorted patients into milestones. At month 30, 47% of acoramidis patients were "alive and not worse" — meaning less than a 5-point drop from baseline — versus 30% on placebo (odds ratio 2.1; number needed to treat 6) [s1]. For "alive and well" (a score above 60 with less than a 10-point decline), the figures were 46% versus 31% (number needed to treat 7); for "alive and better" (a rise of more than 5 points), 25% versus 14% (number needed to treat 9) [s1]. In plain terms, a quarter of treated patients were not merely holding steady but actually improved, against one in seven on placebo.

How to read it

The value of this analysis is that it closes a common gap in cardiology trials: a mortality or hospitalisation benefit that never shows up in what patients experience. Here the two point the same way, and the numbers-needed-to-treat are small enough to matter in a disease this serious [s1]. The limits are the usual ones. ATTRibute-CM was an industry-funded trial; the health-status milestones, though prespecified in spirit, include post-hoc "alive and well/better" cut-points, and questionnaire scores in a trial where patients die over 30 months require careful handling of missing data, which the authors addressed but which always leaves room for argument [s1].

Acoramidis is a stabiliser — it props up TTR rather than switching it off. That contrasts with the gene-silencing approach, which lowers how much TTR is made at all, and which missed its primary endpoint for eplontersen in a competing heart-amyloid trial. The older stabiliser tafamidis established the class, and the widening set of options has already strained health systems deciding what to fund, as the divergence between Australian and New Zealand subsidy decisions shows.

What to watch

The open questions are how acoramidis compares directly with tafamidis and with the silencers, none of which ATTRibute-CM tested head-to-head, and whether the health-status benefit widens or plateaus with longer follow-up [s1][s2]. This article describes research and is not medical advice; treatment of cardiac amyloidosis is a decision for treating clinicians.

Sources

• Effect of Acoramidis on Heart Failure–Related Health Status: A Secondary Analysis of the ATTRibute-CM Randomized Clinical Trial — JAMA Cardiology, 29 July 2026
• Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy — New England Journal of Medicine, 2024